These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23455440)

  • 41. [Huntington disease. A review].
    Bonilla E
    Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
    Lee CY; Cantle JP; Yang XW
    FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease.
    Haun F; Nakamura T; Shiu AD; Cho DH; Tsunemi T; Holland EA; La Spada AR; Lipton SA
    Antioxid Redox Signal; 2013 Oct; 19(11):1173-84. PubMed ID: 23641925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
    Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
    Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
    Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
    Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.
    Harris AS; Denovan-Wright EM; Hamilton LC; Robertson HA
    J Psychiatry Neurosci; 2001 Mar; 26(2):117-22. PubMed ID: 11291528
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
    Farrar AM; Callahan JW; Abercrombie ED
    Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deregulation of BRCA1 leads to impaired spatiotemporal dynamics of γ-H2AX and DNA damage responses in Huntington's disease.
    Jeon GS; Kim KY; Hwang YJ; Jung MK; An S; Ouchi M; Ouchi T; Kowall N; Lee J; Ryu H
    Mol Neurobiol; 2012 Jun; 45(3):550-63. PubMed ID: 22580959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F; Fischhaber PL; Guo C; Tang TS
    Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.
    Olson SD; Kambal A; Pollock K; Mitchell GM; Stewart H; Kalomoiris S; Cary W; Nacey C; Pepper K; Nolta JA
    Mol Cell Neurosci; 2012 Mar; 49(3):271-81. PubMed ID: 22198539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability.
    Fu Z; Liu F; Liu C; Jin B; Jiang Y; Tang M; Qi X; Guo X
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1428-1435. PubMed ID: 30802639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
    Sadri-Vakili G; Cha JH
    Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
    Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
    Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux.
    Lee H; Noh JY; Oh Y; Kim Y; Chang JW; Chung CW; Lee ST; Kim M; Ryu H; Jung YK
    Hum Mol Genet; 2012 Jan; 21(1):101-14. PubMed ID: 21954231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease.
    Chiang MC; Chen HM; Lee YH; Chang HH; Wu YC; Soong BW; Chen CM; Wu YR; Liu CS; Niu DM; Wu JY; Chen YT; Chern Y
    Hum Mol Genet; 2007 Mar; 16(5):483-98. PubMed ID: 17213233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.